Trial · NCT04984837
Study of Lacutamab in Peripheral T-cell Lymphoma
NCT04984837, Phase 2, Active not recruiting, The Lymphoma Academic Research Organisation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Lacutamab in Peripheral T-cell Lymphoma. Trials, record NCT04984837. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04984837
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Lacutamab in Peripheral T-cell Lymphoma
- NCT number
- NCT04984837
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 49 participants, actual
- Lead sponsor
- The Lymphoma Academic Research Organisation
- Conditions
- Peripheral T Cell Lymphoma, Relapse/Recurrence
- Interventions
- Lacutamab, Gemcitabine, Oxaliplatine
- First posted
- 2021-08-02
- Last updated
- 2026-06-04
Source ClinicalTrials.gov
Registered outcomes35
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | median modified progression-free survival (mPFS) - CT-based | 5,5 years. | time from randomization until one of the following events occurs, whichever comes first: 1. Disease progression (PD) 2. Administration of any additional unplanned anti-lymphoma treatment (except allogeneic or autologous hematopoietic cell transplantations (HCT)) 3. Relapse after achievement of CR 4. Death due to any cause. PD and relapse will be evaluated according to Lugano 2014 criteria (CT-based). |
| Secondary | median modified progression-free survival (mPFS) - PET-based | 5,5 years. | |
| Secondary | Number of Adverse Events | 5,5 years. | |
| Secondary | overall survival (OS) | 5,5 years. | |
| Secondary | complete response rate (CRR) Lugano 2014 criteria (CT-based) | 5,5 years. | |
| Secondary | complete response rate (CRR) Lugano 2014 criteria (PET-based) | 5,5 years. | |
| Secondary | overall response rate (ORR) Lugano 2014 criteria (CT-based) | 5,5 years. | |
| Secondary | overall response rate (ORR) Lugano 2014 criteria (PET-based) | 5,5 years. | |
| Secondary | response rate assessed by Deauville criteria | 5,5 years. | |
| Secondary | duration of response (DOR), | 5,5 years. | 1. Disease progression (PD) 2. Administration of any additional unplanned anti-lymphoma treatment (except allogeneic or autologous hematopoietic cell transplantations (HCT)) 3. Relapse after achievement of CR 4. Death due to any cause |
1 to 10 of 35Source ClinicalTrials.gov
See all 35 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 35687761 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04984837
GET https://conductscience.org/api/trials/v1/NCT04984837/registered?page=2